Insight

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma – Journal of Clinical Oncology

Salah Eddine O. Kacimi/researchgate.net

Oct 15, 2024, 16:40

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma – Journal of Clinical Oncology

Journal of Clinical Oncology shared a post on X:

“Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.”

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

Authors: Salah Eddine O. Kacimi, et al.

First-Line Procarbazine, CCNU, and Vincristine With Radiotherapy in IDH-Mutant Oligodendroglioma - Journal of Clinical Oncology

cancer cancer awareness cancer care CCNU fight against cancer Global fight against cancer JCO Journal of Clinical Oncology Oligodendroglioma OncoDaily Oncology Procarbazine radiotherapy Salah Eddine O. Kacimi

World’s Nicest Judge Frank Caprio Dies at 88 After Brave Battle with Pancreatic Cancer

IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

Ruben Mesa is Starting a New Position as President of Cancer National Service Line at Advocate Health

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Dana Dornsife: After 19 Years, Lazarex Cancer Foundation Is Shuttering Because of Lack of Funding